This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

52/100

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Getting a diagnosis

Topic: Brain proteins, microglia and lab models

After expert panel review, only 50/67 patients met consensus criteria for DLB, 26/151 controls had a reduced MoCA, and 120/151 controls had a normal MoCA. The proportions of subjects with cutaneous P-SYN detected by skin biopsy were 96.0% (48 of 50) of the DLB group, 31% (8 of 26) of the controls with reduced MoCA, and 3.3% (4 of 120) of the controls with normal MoCA. In this prospective, blinded, cross-sectional study, a high proportion of subjects meeting clinical consensus criteria for DLB had P-SYN detected in skin biopsies. Almost 1/3 of subjects with reduced MoCA testing also had P-SYN detected. These results support a role for skin biopsy detection of P-SYN in patients with DLB. TRIAL REGISTRATION: NCT04700722.

Key findings

After expert panel review, only 50/67 patients met consensus criteria for DLB, 26/151 controls had a reduced MoCA, and 120/151 controls had a normal MoCA.
The proportions of subjects with cutaneous P-SYN detected by skin biopsy were 96.0% (48 of 50) of the DLB group, 31% (8 of 26) of the controls with reduced MoCA, and 3.3% (4 of 120) of the controls with normal MoCA.
In this prospective, blinded, cross-sectional study, a high proportion of subjects meeting clinical consensus criteria for DLB had P-SYN detected in skin biopsies.
Almost 1/3 of subjects with reduced MoCA testing also had P-SYN detected.
These results support a role for skin biopsy detection of P-SYN in patients with DLB.

Why it matters

This cross-sectional study found that a high proportion of subjects meeting clinical criteria for dementia with Lewy bodies had phosphorylated alpha-synuclein detected in skin biopsies. It supports a role for skin biopsy detection in diagnosis, not treatment, cure, or prevention.

New to this subject? Start with our plain-English guide: Getting a diagnosis →

Study details

Study designcross-sectional
Participants151
Effect size96.0%; 3.3%
Evidence strengthLow

How this study scored 52/100

Published in a peer-reviewed journal, and it is a snapshot of people at one point in time. Scored zero for randomised / blinded because the record does not state it.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (Annals of Clinical and Translational Neurology)
Journal's citation record	1 / 4	Annals of Clinical and Translational Neurology: journal h-index 97 (OpenAlex, 2026-10-29)
Study design	4 / 12	A snapshot of people at one point in time
Strength of evidence	1 / 5	Rated “low” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	4 / 5	2025 — within 3 year(s) of the newest study here
Sample size	2 / 4	151 participants
Effect reported	2 / 3	Effect reported as a number, without an interval or test
Studied in people	3 / 3	Studied in people (participant count stated)
Randomised / blinded	0 / 2	No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	1 / 7	Cited 3 times (OpenAlex, 2026-10-10)
Citations per year	1 / 5	1.0 citations a year over 3 year(s) since 2025
Impact for its field and year	2 / 6	Cited 1.7× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	0 / 6	No other study in this library cites it
Still being cited	1 / 4	Cited 3 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	3 / 4	Last-listed author Roy L. Freeman: h-index 83 (OpenAlex, whole career)
Institution's track record	3 / 3	Harvard University: institution h-index 3,235 (OpenAlex)
Multi-centre collaboration	3 / 3	OpenAlex lists 25 institution(s) in 1 country
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 41449577)
Free to read	2 / 2	Free to read
Total	52 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

APA 7th

Gibbons, C. H., Levine, T., Adler, C. H., Bellaire, B., Wang, N., Agarwal, P., et al. (2025). Cutaneous Phosphorylated Alpha‐Synuclein in Lewy Body Dementia. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.70291

Vancouver

Gibbons CH, Levine T, Adler CH, Bellaire B, Wang N, Agarwal P, et al. Cutaneous Phosphorylated Alpha‐Synuclein in Lewy Body Dementia. Annals of Clinical and Translational Neurology. 2025. doi:10.1002/acn3.70291. PMID: 41449577.

BibTeX

@article{gibbons2025-41449577,
  author  = {Gibbons, Christopher H. and Levine, Todd and Adler, Charles H. and Bellaire, Bailey and Wang, Ningshan and Agarwal, Pinky and Aldridge, Georgina M. and Barboi, Alexandru and others},
  title   = {{Cutaneous Phosphorylated Alpha‐Synuclein in Lewy Body Dementia}},
  journal = {Annals of Clinical and Translational Neurology},
  year    = {2025},
  doi     = {10.1002/acn3.70291},
  pmid    = {41449577},
  url     = {https://doi.org/10.1002/acn3.70291}
}

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Getting a diagnosis

Also tagged “bodies”

1,017 studies in the library carry the topic tag “bodies”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,017 tagged studies.

Similar studies

More on Getting a diagnosis

See all studies in Getting a diagnosis →